Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to lymphokine – cytokine – or other secreted growth...
Patent
1997-02-18
1998-12-01
Hollinden, Gary E.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to lymphokine, cytokine, or other secreted growth...
424 111, 424 91, A61K 5100, A61M 3614
Patent
active
058433970
ABSTRACT:
Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agents can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy.
REFERENCES:
patent: 4046722 (1977-09-01), Rowland
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4604377 (1986-08-01), Fernandes et al.
patent: 4624846 (1986-11-01), Goldenberg
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4683199 (1987-07-01), Palladino
patent: 4690915 (1987-09-01), Rosenberg
patent: 4724232 (1988-02-01), Rideout et al.
patent: 4734279 (1988-03-01), Stephan et al.
patent: 4752925 (1988-06-01), Martin et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4894227 (1990-01-01), Stevens et al.
patent: 5100378 (1992-03-01), Morgan, Jr.
patent: 5120525 (1992-06-01), Goldenberg
patent: 5200176 (1993-04-01), Wong et al.
patent: 5230886 (1993-07-01), Treon et al.
patent: 5399338 (1995-03-01), Born et al.
patent: 5609846 (1997-03-01), Goldenberg
Smith et al., "Increased Survival In Irradiated Animals Treated With Bacterial Endotoxins",Am. J. Physiol, vol. 109:124-130, (1957).
Mefferd et al., "Effect Of Piromen On Survival Of Irradiated Mice", Proc. Soc. Exp. Biol. Med., vol. 83:54-63, (1953).
Ainsworth et al., "Effect Of Microbial Antigens On Irradiation Mortality In Mice", Proc. Soc. Exp. Biol. Med., vol. 102:483-489, (1959).
Broudy et al., "Interleukin 1 Stimulates Human Endothelial Cells To produce Granulocyte-Macrophage Colony Stimulating Factor And Granulocyte Colony-Stimulating Factor",J. Immunol., vol. 139:464-468, (1987).
Takacs et al., "IL 1 Induction By Murine T Cell Clones: Detection Of An IL 1-inducing Lymphokine" J. Immunol., vol. 138:2124-2131, (1985).
Neta et al., "Interdependence Of The Radioprotective Effects Of Human Recombinant Interleukin 1 .alpha., Fumor Necrosis Factor .alpha., Granulocyte Colony-Stimulating Factor, And Murine Recombinant Granulocyte-Macrophage Colony-Stimulating Factor",J. Immunol., vol. 140(1):108-111, (1988).
Moore et al., "Synergy Of Interleukin 1 And Granulocyte Colony-Stimulating Factor: In Vivo Stimulation Of Stem-Cell Recovery And Hematopoietic Regeneration Following 5-Fluorouracil Treatment Of Mice", Proc. Natl. Acad. Sci., USA, vol. 84:7134-7138, (1987).
Dinarello, (Rev. Infectious Dis.) vol. 6:51-95, (1984).
Oppenheim et al., "There Is More Than One Interleukin 1",Immunol. Today, vol. 7:45-56, (1986).
Farrar et al., "Participation Of Lymphocyte Activating Factor (Interleukin 1) In The Induction Of Cytotoxic T Cell Responses", J. Immunol., vol. 124:1371-1377, (1980).
Mccarthy et al., "Suppression of Food Intake During Infection: Is Interleukin-1 Involved",Am. J. Clin. Nutr., vol. 42:1179-1182, (1985).
Nawroth et al. "Interleukin 1 Induces Endothelial Cell Procoagulant While Suppressing Cell-Surface Anticoagulant Activity",Proc. Natl. Acad. Sci. USA, vol. 83:3460-3464, (1986).
Granstein et al., "In Vivo Inflammatory Activity Of Epidermal Cell-Derived Thymocyte Activating Factor And Recombinant Interleukin 1 In The Mouse", J. Clin. Invest., vol.77:1020-1027, (1986).
Dukovich et al., "Stimulation of Fibroblast Proliferation And Prostaglandin Production By Purified Recombinant Murine Interleukin 1", Clin. Immunol. Immunopathol., VO; 38:381-389, (1986).
Bauer et al., "Murine Interleukin 1 Stimulates .alpha..sub.2- Macroglobulin Synthesis In Rat Hepatocyte Primary Cultures", Febs Lett., Vol. 190(2):271-274, (1985).
Hall et al., "Stimulation of Endothelial Cell Prostacyclin Formation by Interleukin-2", Lymphokine Res.,vol. 5:87-96, (1986).
Tocco-Bradley et al., "The Biological Activity in Vivo of Recombinant Murine Interleukin 1 In The Rat", Proc. Soc. Exp. Biol. Med.,vol. 182:263-271, (1986).
Gubler et al., "Recombinant Human Interleukin 1.alpha.: Purification And Biological Characterization", J. Immunol.,vol. 136:2492-2497, (1986).
Kilian et al., "Interleukin 1.alpha. and Interleukin 1.beta. Bind To The Same Receptor On T Cells", J. Immunol.,vol. 136(12):4509-4514, (1986).
Levine et al., "The Stimulations Of Archidonic Acid Metabolism By Recombinant Murine Interleukin 1 And Tumor Promoters Or 1-Oleoyl-2-Acetyo-Gglycerol Are Synergistic", Jo. Immunol., vol. 135(5):3430-3433, (1985).
Karin et al., "Iinterleukin 1 Regulates Human Metallothionein Gene Expression", Mol. Cell. Biol., vol. 5(10):2866-2869, (1985).
Ramadori et al., "Pretranslational Modulation Of Acute Phase Hepatic Protein Synthesis By Murine Recombinant Interleukin 1 (IL-1) And Purified Human IL-1", J. Exp. Med., vol. 162:930-942, (1985).
Nakamura et al., Gann,vol. 77:1734-1739, (1986).
Nakata et al., "Augmented Antitumor Effect of Recombinant Human Interleukin-1.alpha. By Indomethacin", Cancer Res., vol. 48:584-588, (1988).
Lee et al.,Experimental Hematology, vol. 15:983-988, (1987).
Griffin, Jour. Clin. Oncology, vol. 7:151-155, (1989).
Perlmutter et al., "Regulation of Class III Major Histocompatibility Complex Gene Products By Interleukin-1", Science, vol. 232:850-852, (1986).
Gowen et al., "Actions of Recombinant Interleukin 1, Interleukin 2, and Interferon-.gamma. oN Bone Resotrption In Vitro", J.Immunol.,vol. 136:2478-2482, (1986).
Woloski et al., "Corticotropin-Releasing Activity of Monolines",Science, vol. 230:1035-1037, (1985).
Beutler et al., "Purification Of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted By Endotoxin-Induced Raw 264.7 Cells", J. Exp.. Med., vol. 161:984-995, (1985).
Pike et al., "Interleukin 1 Can Act As A B-Cell Growth And Differentiation Factor", Proc. Natl. Acad. Sci. USA, vol. 82:8153-8157, (1985).
Bussolino et al., "Interleukin 1 Stimulates Platelet-Activating Factor Production In Cultured Human Endothelial Cells",J. Clin. Invest., vol. 77:2027-2033,(1986).
Lovett et al., "Macrophage Cytotoxicity: Interleukin 1 As A Mediator Of Tumor Cytostasis", J. Immunol.,vol. 136:340-347, (1986).
Onozaki et al., "Role Of Interleukin 1 In Promoting Human Monocyte-Mediated Tumor Cytotoxicity",J. Immunol., vol. 135:314-320, (1985).
Herrmann et al.,Jour. Clin. Oncology, vol. 7:159-167, (1989).
Brandt et al, N. Engl. J. Med., vol. 318:869-876, (1988).
Gabrilove et al., N. Engl. J. Med., vol. 318:1414-1422, (1988).
Boraschi et al., J. Exp. Med., vol. 168:675-686, (1988).
Neta et al., The Journal of Immunology, vol. 136:2483-2485, (1987).
Lomedico et al., "Molecular Biology of Interleukin-1," Cold Spring Harbor Symp. Quan. Biology, vol. L1:631-639, (1986).
Donahue, et al., "Stimulation of Haematopoiesis In Primates By Continuous Infusion Of Recombinant Human GM-CSF", Nature, vol. 321:872-875, (1986).
Nienhuis et al., "Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Shortens The Period Of Neutropenia After Autologous Bone Marrow Transplantation In A Primate Model", J. Clin. Invest., vol. 80:573-577, (1987).
Vogel et al., "Induction of Colony Stimulating Factor In Vivo by Recombinant Interleukin 1.alpha. and Recombinant Tumor Necrosis Factor .alpha..sup.1 ",The Journal of Immunology, vol. 138:2143-2148, (19987).
Hollinden Gary E.
Immunomedics Inc.
Jones Dameron
LandOfFree
Cytotoxic therapy for graft rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxic therapy for graft rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxic therapy for graft rejection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2393183